The FDA approval is based on a Phase III trial, SOLAR-1, in which the combination nearly doubled median progression free survival.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.